Search the Newsreel

Bausch Health stock gains after Q2 2026 beat (BHC:NYSE)

Bausch + Lomb (BLCO) Stock Rallies On Margin Gains As Losses Narrow

Premium IOLs Help Propel Strong Q2 as Bausch + Lomb Reports Growth and Raises 2026 Guidance

Bausch + Lomb (NYSE/TSX: BLCO) reported strong second-quarter 2026 financial results, with total revenue increasing by 9 percent to $1.394 billion, driven by double-digit growth in surgical and pharmaceuticals. The company also raised its full-year 2026 revenue guidance. This growth was significantly propelled by …

Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends

Bausch & Lomb reported $1.4 billion in revenue, exceeding FactSet consensus by 2% and showing 9% year-over-year growth, though adjusted EPS of $0.17 was 3% below consensus. Despite the mixed earnings, shares remained flat. The report highlights strong first-half performance, indicating that the company's …

Bausch + Lomb Upgrades Full-Year Outlook on Strong Second Quarter

Bausch + Lomb has upgraded its full-year outlook following a strong second quarter performance. This positive revision indicates the company's robust financial health and optimistic projections for the remainder of the year.

Bausch & Lomb Corp 2026: Revenue $1.39B, EPS ($0.04) — 10-Q Summary

Bausch & Lomb Corp (BLCO) reported strong second-quarter 2026 results with revenue reaching $1.39 billion, an increase driven by pricing and volume gains across segments. The company significantly reduced its net loss compared to the prior year, with diluted loss per share narrowing to …

Bausch & Lomb Corp (BLCO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Bausch & Lomb Corp (NYSE:BLCO) reported 8% constant currency revenue growth, showcasing consistent performance across …

Bausch + Lomb Corporation Raises Earnings Guidance for the Full Fiscal Year 2026

Bausch + Lomb Corporation has updated its earnings guidance for the full fiscal year 2026, raising its revenue expectations. The company now anticipates revenue to fall between $5.440 billion and $5.540 billion, an increase from its previous forecast of $5.420 billion to $5.520 billion.

Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was …

Earnings Flash (BLCO) Bausch + Lomb Corporation Posts Q2 Adjusted EPS $0.15 per Share, Vs. FactSet Est of $0.15

Bausch + Lomb Corporation (BLCO) announced its Q2 adjusted earnings per share (EPS) of $0.15, meeting FactSet's estimate. This financial report provides key insights into the company's performance for the second quarter.

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Revenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14 Million Adjusted EBITDA (non-GAAP)1 of $241 Million; Adjusted EBITDA Excluding …

Bausch + Lomb (NYSE: BLCO) lifts revenue but remains loss-making

Is Bausch + Lomb (BLCO) Undervalued As EyeGility Launch And Earnings Draw Focus?

Bausch + Lomb Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-07-29

Bausch + Lomb (BLCO) reported strong Q2 2026 results, with an 8% constant currency revenue growth and a 28% increase in adjusted EBITDA, leading to a 17.6% adjusted EBITDA margin. The company raised its full-year revenue and adjusted EBITDA guidance, driven by consistent performance …

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 9.1% year on year to $1.39 billion. The company expects the full year's revenue to be around …

Bausch + Lomb: Q2 Earnings Snapshot

Bausch + Lomb Corporation reported a Q2 loss of $14 million, or 4 cents per share, which adjusted to 16 cents per share, meeting Wall Street expectations. The company recorded revenue of $1.39 billion, exceeding analyst forecasts, and anticipates full-year revenue between $5.42 billion …

Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Bausch + Lomb Corp (BLCO), rating its current risk score at 7.06, placing it 43rd out of 199 in the Healthcare Equipment & Supplies industry. Key metrics include a beta of 0.58, indicating lower volatility compared to …

Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System

Bausch + Lomb has launched its new EyeGility Inserter preloaded IOL delivery system in the U.S. This system is designed for use with enVista Aspire and Envy IOLs, offering convenient one-handed operation and smooth delivery with a silicon soft-tipped plunger. The EyeGility Inserter aims …

Bausch + Lomb Corporation Revenue Breakdown – MUN:S2L

Bausch + Lomb Corporation (MUN:S2L) generated €4.34 billion in revenue last year, with its Vision Care segment contributing the most at €2.49 billion. Geographically, the United States and Puerto Rico was the largest source of revenue, accounting for €2.17 billion. This data provides a …

Investor Outlook: Bausch + Lomb Corporation (BLCO) Eyes 12% Upside Potential Amid Steady Growth

Bausch + Lomb Corporation (BLCO), a healthcare company specializing in medical instruments, shows a stable performance with an intriguing opportunity for investors. Despite negative EPS and ROC, the company demonstrates strong revenue growth and free cash flow, indicative of strategic reinvestment for long-term growth. …

Bausch + Lomb Corp (BLCO) Cash Flow

This article provides an in-depth look at Bausch + Lomb Corp's (BLCO) cash flow statements, including operating, investing, and financing activities, presented quarterly and annually. It details changes in various cash flow components over several fiscal quarters and years, offering insights into the company's …

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here's what to expect. Bausch + Lomb beat analysts' revenue expectations last quarter, reporting revenues of $1.24 billion, up …

Bausch + Lomb Corp (BLCO) Institutional Confidence

Bausch + Lomb Corp (BLCO) has an institutional shareholding score of 3.00, ranking 131 out of 200 in its industry, with the institutional shareholding proportion decreasing by 34.15% quarter-over-quarter to 11.30%. Carl Icahn is the largest institutional shareholder, holding 3.54 million shares, representing 0.98% …

Bausch + Lomb Corporation (BLCO) Gets a Hold from Wells Fargo

Wells Fargo maintained a Hold rating on Bausch + Lomb Corporation (BLCO) with an $18.00 price target. Goldman Sachs also issued a Hold rating, while RBC Capital maintained a Buy rating. Bausch + Lomb reported Q1 revenue of $1.24 billion and a GAAP net …

Bausch + Lomb launches EyeGility preloaded IOL delivery system in US

Bausch + Lomb has launched its EyeGility Inserter, a single-use preloaded delivery system for its enVista intraocular lens (IOL) platform, in the US. This new system aims to streamline cataract surgery by eliminating manual lens loading and featuring a push-type plunger for smooth IOL …

3 Reasons to Avoid BLCO and 1 Stock to Buy Instead

3 Reasons to Avoid BLCO and 1 Stock to Buy Instead Over the past six months, Bausch + Lomb's stock price fell to $15.99. Shareholders have lost 7% of their capital, which is disappointing considering the S&P 500 has climbed by 7.7%. This may …

Bausch + Lomb (BLCO) Expected to Release Quarterly Earnings on Wednesday

Bausch + Lomb launches EyeGility Inserter to streamline cataract lens delivery in US

Bausch + Lomb Corporation has launched its new EyeGility Inserter preloaded IOL delivery system in the US. This new system is designed to simplify lens delivery during cataract surgery and is built for the enVista Aspire and upcoming enVista Envy IOLs, providing smooth, controlled …

BHC5652799 Bond Profile — Key Metrics

This article provides key metrics for the Bausch + Lomb Corporation 8.375% 01-OCT-2028 bond (BHC5652799). It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. The profile also includes a description of Bausch + Lomb's business segments, covering Vision …

Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says

RBC Capital Markets highlighted that Bausch + Lomb's prescription drug segment is a key growth driver that could positively impact its second-quarter results. Strong performance in this division, particularly with products like Miebo and other ophthalmology treatments, is expected to help the company meet …

Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.

Bausch + Lomb BLCO recently announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery system designed for its enVista family of IOLs. The system is now available for enVista Aspire preloaded IOLs, while enVista Envy lenses integrated with the …

Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Bausch + Lomb (BLCO) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, outlining its strategic vision focused on selling excellence, operational reliability, R&D, and financial excellence. The company aims for 5-7% top-line growth and increased EBITDA margins from 17% to …

Bausch + Lomb launches EyeGility IOL delivery system in U.S.

Bausch + Lomb has launched its EyeGility Inserter preloaded IOL delivery system in the U.S., designed for the enVista family of intraocular lenses. This system offers one-handed operation and balanced push force for lens delivery through a small incision, improving surgical efficiency. The company's …

Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant

Bausch + Lomb announced that its BL1107 candidate failed to meet its primary endpoint in a phase 2 glaucoma trial, which aimed to replicate visual function improvements seen in an earlier phase 1/2a study. While the drug did achieve intraocular pressure reduction, it did …

Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21

Goldman Sachs has reiterated a Hold rating on Bausch + Lomb Corp. (BLCO.US) stock. The firm also increased its price target for BLCO.US shares to $21. This indicates a continued cautious but slightly more optimistic outlook on the company's stock by Goldman Sachs.

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

Bausch + Lomb has launched its EyeGility™ Inserter preloaded IOL delivery system in the U.S., designed for the enVista® family of intraocular lenses. This system offers convenient one-handed operation and balanced push force for smooth delivery, aiming to improve efficiency and comfort for surgeons. …